IP Library Granted Patent US 8,858,977
Granted Patent B2
US 8,858,977 · App. 13/673,162 · Granted Oct 14, 2014

Drug delivery system

Inventors: Rudolf Johannes Joseph Groenewegen (Oss, NL); Wouter de Graaff (Oss, NL); Henk Jan Out (Oss, NL)
Assignee: Merck Sharp & Dohme B.V.
A61K9/0036A61K31/567A61K9/209A61K9/00A61K31/57A61K31/565A61K9/0092A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,858,977
App. No.
13/673,162
Granted
Oct 14, 2014
Kind
B2
Abstract

The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.

Claims (16)

1. A drug delivery system comprising (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first steroid and with (b) a second steroid in dissolved form and wherein said core is loaded with said second steroid such that steroid in the core is present only in dissolved form.

2. A drug delivery system according to claim 1 , wherein the delivery system has a substantially ring-shaped form and is intended for vaginal administration.

3. A drug delivery system according to claim 1 , wherein at least the skin but optionally also the core and the intermediate layer comprise ethylene-vinylacetate copolymer as the thermoplastic polymer.

4. A drug delivery system according to claim 3 , wherein the core and the intermediate layer comprise the same grade of ethylene-vinylacetate copolymer as the thermoplastic polymer.

5. A drug delivery system according to claim 3 , wherein the core and the intermediate layer comprise a different grade of ethylene-vinylacetate copolymer as the thermoplastic polymer.

6. A method of manufacturing the three-layered drug delivery system of claim 1 comprising:

(i) producing a loaded homogenous polymer core granulate and a loaded homogenous polymer intermediate layer granulate;

(ii) co-extruding the core granulate and the intermediate layer granulate with a polymer skin granulate to form the three-layered drug delivery system.

7. A method according to claim 6 wherein step (i) comprises:

(a) grinding the polymer;

(b) dry powder mixing the ground polymer with the active compounds to be loaded in the intermediate layer;

(c) dry powder mixing the ground polymer with the active compound to be loaded in the core;

(d) blend extruding the resulting powder mixtures of steps (b) and (c);

(e) cutting the resulting loaded polymer strands into granules, thereby obtaining a core granulate and an intermediate layer granulate;

(f) lubricating both core granulate and intermediate granulate with a lubricant;

wherein steps (b) and (c) are interexchangeable.

Assignments (2)
MERGER Recorded Jul 31, 2013
From: MSD OSS B.V.
To: ORGANON BIOSCIENCES NEDERLAND B.V.
Reel/Frame 030913/0691 →
MERGER Recorded Jul 31, 2013
From: ORGANON BIOSCIENCES NEDERLAND B.V.
To: MERCK SHARP & DOHME B.V.
Reel/Frame 030914/0713 →
Priority Claims (1)
EP 03101490 · May 23, 2003 · regional
Continuity (3)
Continuation 10558040
Provisional Application 60473055 · May 23, 2003
Related Publication 20130078286A1 · Mar 28, 2013